Anteris Technologies Global Cor (AVR) Fair Value 2026

AVR · Medical Instruments & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.1 /10

32 fundamental signals · 10 models active

Value Trap Risk

— (—/100)

Quick Summary — As of 2026-07-15, Anteris Technologies Global Cor (AVR) trades at $8.69, approximately 118% above CirclFi’s Bayesian DCF fair value of $3.99. QOC: 6.1/10. 10/13 models active.

Key Facts

Ticker
AVR
Price
$8.69
Quality Score
6.1/10
Value Trap Risk
—/100
Models Active
10/13
Last Updated
Strength: 10 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Anteris Technologies Global Cor (AVR) Undervalued or Overvalued in 2026?

According to CirclFi’s 10-model valuation engine, Anteris Technologies Global Cor (AVR) appears overvalued as of : the median of 10 independent fair value estimates is $3.33, 61.7% below the current price of $8.69. Estimates range from $0.45 to $8.57. AVR scores 6.1/10 on fundamental quality and —/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Anteris Technologies Global Cor Stock in 2026? →

Valuation Matrix

10 Intrinsic Value Models vs. Current Price ($8.69)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $3.99 -54.1%
Earnings Power Value
Low Conviction
 $2.52 -71.0%
CUCE Ensemble
Low Conviction
 $3.87 -55.5%
First Chicago
Medium Conviction
 $0.45 -94.9%

Unlock the Full Matrix

Access 6 additional models including EROIC Spread, Dynamic NAV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is Anteris Technologies Global Cor (AVR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Anteris Technologies Global Cor's intrinsic value is estimated at $3.67, suggesting the stock is overvalued at its current price of $8.69. With 9 out of 10 models flagging downside (-57.7% average return), the market may be pricing in unsustainable growth. Model dispersion is worth noting: PWERM targets $8.57 (-1.4%), versus First Chicago at $0.45 (-94.9%). This +93.5% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About AVR?

10 of 13 models are currently active for AVR. All 10 active models suggest the stock trades above fair value. The Bayesian DCF estimates AVR's intrinsic value at $3.99, implying -54.1% downside from the current price. See which stocks rank higher →

How Does AVR Rank in Medical Instruments & Supplies?

Among 7 Medical Instruments & Supplies stocks, AVR ranks #6 by Quality of Company score. CirclFi's QOC score of 6.1/10 evaluates 32 fundamental signals. A score of 6.1 indicates above-average quality.

Anteris Technologies Global Cor operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is AVR a Value Trap?

The Value Trap algorithm is not active for AVR. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for Anteris Technologies Global Cor. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Anteris Technologies Global Cor is rated at 6.1/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

The gap between the most bullish and bearish model spans +93.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every AVR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across AVR's 10 active models, average confidence is 24%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Anteris Technologies Global Cor Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Instruments & Supplies Stocks Should You Also Analyze?

6 related Medical Instruments & Supplies stocks with 13-model coverage

ATRAptarGroup, Inc.QOC 9.6ALGNAlign Technology, Inc.QOC 9.2AVTRAvantor, Inc.QOC 9.2ATRCAtriCure, Inc.QOC 7.7ANGOAngioDynamics, Inc.QOC 6.4ALCAlcon Inc.QOC 2.0

Read investment analysis: ATR · ALGN · AVTR · ATRC · ANGO

Frequently Asked Questions About Anteris Technologies Global Cor

What is Anteris Technologies Global Cor's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Anteris Technologies Global Cor (AVR) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $3.99. The Quality of Company score is 6.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is AVR overvalued or undervalued right now?

At $8.69, 0 of 10 active models suggest AVR may be undervalued, while 10 indicate potential overvaluation. The median of all 10 fair value estimates is $3.33, 61.7% below the current price of $8.69 — a consensus view that AVR is overvalued. The assessment depends on which methodology best fits Anteris Technologies Global Cor's business model in Medical Instruments & Supplies.

What does a Quality of Company score of 6.1 mean for AVR?

Anteris Technologies Global Cor's QOC of 6.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on AVR?

CirclFi analyzes AVR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Is AVR a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for AVR at this time. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 10-model valuation engine, Anteris Technologies Global Cor (AVR) has a median fair value of $3.33 — 61.7% below the current price of $8.69 — as of 2026-07-15.” Source: circlfi.com/stock/AVR/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on AVR.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access